Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Cisplatin-Mitomycin-Vinblastine Regimen

Known as: MVP Regimen 
A regimen consisting of cisplatin, mitomycin and vinblastine used to treat advanced-stage non-small cell lung cancer.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
OBJECTIVE To investigate the activity and clinical efficacy of toremifene plus mitomycin, vindesin and cisplatin regimen (MVP) in… Expand
Is this relevant?
2003
2003
PURPOSE A prospective Phase I/II dose escalation study was conducted to determine the maximum tolerated dose (MTD) in three… Expand
Is this relevant?
2002
2002
PURPOSE To compare a regimen of vinorelbine and cisplatin (VC) to the combination of mitomycin, vindesine, and cisplatin (MVP) in… Expand
Is this relevant?
2001
2001
The majority of patients diagnosed with non-small cell lung carcinoma (NSCLC) present with advanced disease and, as such, are… Expand
Is this relevant?
2000
2000
Objective: To explore the change of pathology and the clinical response rate treated by neoadjuvant chemotherapy with MVP regimen… Expand
  • table 1
  • table 2
Is this relevant?
Highly Cited
1999
Highly Cited
1999
In a prospective randomized study, 287 patients with advanced non-small cell lung cancer (NSCLC) stage IIIb or IV with ECOG… Expand
Is this relevant?
1998
1998
The aim of this randomised trial was to compare the efficacy of bolus versus continuous infusion cisplatin combined with… Expand
Is this relevant?
1992
1992
Cisplatin has many toxic effects; emesis, impairment of renal function, myelosuppression, peripheral neuropathy, ototoxicity and… Expand
Is this relevant?
1992
1992
Between August 1985 and June 1986, 49 previously untreated patients with locally advanced or metastatic non-small-cell lung… Expand
Is this relevant?